Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and plerixafor

gefitinib has been researched along with plerixafor in 4 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(plerixafor)		Trials
(plerixafor)		Recent Studies (post-2010) (plerixafor)
5,2315662,9191,312113930

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)plerixafor (IC50)
C-X-C chemokine receptor type 4Rattus norvegicus (Norway rat)0.108
C-C chemokine receptor type 2Homo sapiens (human)0.0001
C-X-C chemokine receptor type 4Homo sapiens (human)0.3717

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC1
Ge, D; Gu, J; Liu, Z; Lu, C; Mao, W; Shou, H; Xu, F; Zhang, K; Zhang, Z; Zhu, Q1

Reviews

1 review(s) available for gefitinib and plerixafor

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for gefitinib and plerixafor

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
    International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment

2013
Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

    Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Receptors, CXCR4; RNA, Small Interfering; Smad2 Protein; Transforming Growth Factor beta1; Up-Regulation

2020